Nyxoah (NYXH) Non-Current Deffered Revenue (2024 - 2025)
Nyxoah (NYXH) recorded quarterly Non-Current Deffered Revenue of $792713.6 in Q4 2025, up 52.24% quarter-over-quarter from $520701.5 in Q2 2025, and up 57.17% on a YoY basis from $504377.0 in Q4 2024.
Nyxoah (NYXH) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends
Nyxoah's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $792713.6 for Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue rose 57.17% year-over-year to $792713.6; the TTM figure through Dec 2025 stood at $792713.6 (up 57.17% YoY), while the FY2025 annual figure was $792713.6, up 57.17% from the prior year.
- Non-Current Deffered Revenue was $792713.6 for Q4 2025 at Nyxoah, up from $520701.5 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $792713.6 in Q4 2025 to a low of $387093.5 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | - |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | - |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | - |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 163.15 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 11.80 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | - |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 208.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | - |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | - |
| 10 | Nyxoah | 0.69 | 0.69 | 4.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 792,713.63 |
| Jun 30, 2025 | 520,701.46 |
| Mar 31, 2025 | 387,093.47 |
| Dec 31, 2024 | 504,377.03 |